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Abstract: Herpes simplex virus (HSV), a human pathogenic virus, has evolved several 
strategies to evade the production and function of interferons (IFNs) and cytokines 
generated by the innate immune system to restrict the virus. Equilibrium exists between the 
virus and the immune response, and a shift in this delicate balance either restricts the virus 
or enhances virus spread and tissue damage. Therefore, understanding of the cytokine 
response generated after HSV infection and the underlying virus-cell interactions is 
essential to improve our understanding of viral pathogenesis. This review summarizes the 
current knowledge on induction and evasion of the innate immune response by HSV. 
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1. Introduction  
Herpes simplex virus (HSV) is a very common human pathogenic virus. Clinically, HSV infection 
may give rise to gingivostomatitis, cold sore, keratitis, encephalitis, and genital herpes [1]. The 
diseases are normally self-limiting but in immunocompromised individuals, such as newborns, 
transplantation patients, and AIDS-patients, the virus may cause devastating dissimilated infections 
and encephalitis [1].  
Type I interferons (IFN)s, also known as IFN-, and to a lesser extent type III IFNs (IFN-1-3) 
are important for antiviral response against HSV [2-5]. In addition to their direct antiviral effect, IFNs 
together with proinflammatory cytokines are important signalling molecules for activation and 
attraction of leukocytes to the site of infection.  
Pathogens are a highly diverse group of microbes and viruses. Their detection is therefore a major 
challenge to the immune system. Host defense against infections is initiated by the innate immune 
system, operating on the basis of general pathogen features via pattern recognition receptors (PRRs). 
PRRs detect pathogen-associated molecular patterns (PAMPs) and signal the presence of infection to 
the host, activating host defense, including antiviral (IFN-) and pro-inflammatory cytokine 
(interleukin-1 (IL-1, IL-6, IL-18 and tumor necrosis factor  (TNF-) production. In addition, 
PRRs often initiate programmed cell death (apoptosis) of infected cells.  
Toll-like receptors (TLRs) are the best characterized family of PRRs that recognize PAMPs in 
mammals. There are ten characterized TLRs in humans and they are a class of membrane receptors 
that sense microbes either in the extracellular space or in intracellular endolysosomal compartments. 
The second important group of PRRs that have an important role in recognition of HSV infection are 
retinoid acid inducible gene-I (RIG-I)-like receptors (RLRs), including RIG-I and melanoma 
differentiation-associated gene-5 (MDA-5). They are focused on detecting viral genomic RNA or its 
replication intermediates in the cytoplasm [6]. Finally a third pathway is presumed to recognize DNA 
in the cytoplasm, potentially also genomic DNA from HSV. One suggested DNA receptor is DNA-
dependent activator of IFN Regulatory Factors (DAI) that is able to activate type I IFN production in 
response to cytosolic DNA [7]. However, the role of DAI in the in vivo recognition of cytoplasmic 
DNA has remained controversial. Recently, cytosolic DNA-dependent RNA polymerase III has been 
shown to recognize cytosolic DNA and linked to recognition of HSV and the production of IFN- 
[8,9]. Further studies are required to reveal the specific role of DAI, RNA polymerase III and other 
putative other DNA receptors in activation of innate immune response during virus infection in 
humans. 
To mount an efficient antiviral immune response the cell must recognize the virus and activate a 
number of signalling pathways, including Nuclear Factor kappa B (NF-B), IFN Regulatory Factors 
(IRFs) and Mitogen-Activated Protein Kinase (MAPK) pathways. As summarized in Figure 1, the 
recognition of HSV includes (i) recognition of viral surface glycoprotein via either TLR2 or and yet 
unidentified receptor [10-12], (ii) recognition of HSV viral DNA by TLR9 in endosomes, or in the 
cytosol via either RNA polymerase III or potentially DAI [7,9,13-16], and (iii) the recognition of 
virally-derived double-stranded (ds)RNA recognized by RLRs [16]. Finally, TLR3 plays a role in 
restricting HSV infection evidenced by a recent study showing that humans that bear mutations in 
TLR3 are predisposed to HSV-associated encephalitis [17].  Viruses 2009, 1                                       
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Figure 1. Activation of antiviral and proinflammatory responses during HSV infections. 
HSV is recognized by cells through several mechanisms. (i) Virus-receptor interactions 
can induce intracellular signal transduction leading to cytokine expression. Potential 
recognition receptors include TLR2 and the virus entry mediators HVEM. (ii) Viral 
genomic DNA is recognized by TLR9 and a DNA receptor in the cytoplasm, including 
RNA polymerase III. (iii) Accumulating of viral dsRNA during viral replication is 
potentially sensed through several mechanisms, including TLR3 and the RLRs. (iv) 
Recognition of the virus results in activated signalling pathways, such as the MAPK 
pathway (AP-1), NF-B and IRF3/7 regulating the expression of IFN- and other 
cytokines. 
 
 
To gain time, and potentially also to allow chronic infection, HSV has evolved numerous strategies 
to evade IFN signalling at different stages, including directly affecting JAK/STAT signalling and 
interactions with the IFN-induced antiviral proteins Protein Kinase R (PKR) and the 2’-5’-
Oligoadenylate Synthethase (2’-5’-OAS)/RNaseL system. Furthermore, HSV has means of escaping 
cytokine and IFN production via inhibition of the transcription factors NF-B and IRF3 and IRF7 
signalling pathways, reduction of cytokine mRNA stability and interfering with translation.  
This review presents the current knowledge on antiviral escape mechanisms employed by HSV. 
2. Herpes Simplex Virus and Replication of the Virus Genome 
HSV-1 and HSV-2 are closely related, enveloped, nuclear replicating, double-stranded (ds)DNA 
viruses belonging to the subgroup of alphaherpesvirinae. The two subtypes share 83% homology in Viruses 2009, 1                                       
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the protein coding regions of the genome [18], and exhibit many similar biological functions [1]. 
Because of similarities between the two subtypes, no distinction between HSV-1 and HSV-2 will be 
made in the following sections. The reader is encouraged to consult the primary literature for data on 
the individual HSV subtypes. 
The transcription of viral genes is tightly regulated and has two key features. First, herpes virus 
proteins fall into groups, whose synthesis is coordinately regulated, i.e., all genes within a given group 
are expressed sequentially starting with the immediate early (IE) gene group, followed by the early (E) 
gene group, and finally the late (L) group (Figure 2). The sequential expression occurs because IE 
proteins are required for expression of the E proteins, and E proteins generally are essential for viral 
genome replication, which is a prerequisite for the expression of L proteins [1]. The tegument protein 
VP16 associates with cellular transcription factors to promote the transcription of the five IE mRNAs 
encoding infected cell protein 0 (ICP0), ICP4, ICP22, ICP27, and ICP47. The IE genes are expressed 
in the presence of inhibitors of protein synthesis. The four IE proteins, ICP0, 4, 22, and ICP27, are 
transcriptional and translational regulators of the E and L genes, as well as host genes, whereas ICP47 
interferes with the transporter associated with antigen presentation (TAP)1/TAP2 complex and hence 
antigen presentation through major histocompatibility complex class I (MHC I) [19]. Later sections 
will further address the evasion strategies employed by HSV. Besides being a positive regulator of IE 
and L genes, ICP4 also inhibits expression of the IE genes. ICP4´s negative regulation of IE genes 
provides a halt of IE gene expression during later stages of viral infection. Accumulation of ICP4 and 
ICP27 initiates the expression of E genes, which primarily encode proteins involved in DNA 
replication. E gene products include scavenger enzymes, such as the viral thymidine kinase and 
ribonucleotide reductase, as well as enzymes directly involved in DNA replication, such as the viral 
DNA polymerase and DNA helicase. Finally, the L genes are made after DNA replication has 
occurred. These include structural proteins required for the progeny viral particles, as well as VP16 
and vhs, both of which are incorporated into the viral tegument. The capsid is assembled in the nucleus 
and takes up individual DNA genomes once the capsid is fully assembled [20]. Subsequently, the 
capsids associate with the tegument proteins and bud through the viral glycoprotein-containing nuclear 
membrane. The virions are hereafter incorporated into vesicles and released by exocytosis. 
Alternatively, the virus is released by cell lysis or spread by syncytia formation [1].  
3. Antiviral IFN Response during Early HSV Infection 
The first response in a HSV-infected cell is an inflammatory reaction that includes secretion of 
antiviral substances, such as defensins and nitric oxid and most importantly the production of 
cytokines, including IFNs and chemokines. The aim of the initial innate immune response is to limit 
spread of the infection and, if possible, to eliminate the pathogen. The secreted substances activate and 
attract immune cells and thus help to organize an effective antiviral response.  
The type I IFNs IFN- are key cytokines produced within the very first hours after HSV-infection 
[15,21]. IFN- are important in direct control and inhibition of HSV replication [2,22,23], and this 
occurs in synergy with IFN- [24]. In vivo studies show that IFN- alone can control early HSV 
infection independently of natural killer (NK) cell and lymphocyte activity [25]. Experiments in mice 
also demonstrate the importance of the IFN system in the antiviral defense against HSV infection Viruses 2009, 1                                       
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because uncontrolled virus replication is seen in mice genetically lacking functional IFN--receptors 
or when mice are administered neutralizing antibodies against IFN- [3,26]. The studies in mice 
have been supported by the recording that patients lacking functional STAT1, an essential components 
of the IFN pathways, are more prone to HSV encephalitis [4]. Furthermore, IFN- is part of a 
positive feedback loop that amplifies the cytokine response during HSV infection [27]. Though studies 
have established an important role for IFN- in antiviral defense, it is difficult to determine whether 
IFN-´s contribution to viral clearance is primarily mediated by direct antiviral mechanisms or by a 
indirect immunoregulatory mechanisms.  
Figure 2. The replication cycle of HSV. After virus entry, the viral capsid is transported to 
the nucleus and the genome released into the nucleus through nuclear pores. Viral 
tegument proteins released into the cell support IE gene transcription or mediate takeover 
of the cell. The IE proteins are mainly trans-activators that enhance the expression of E 
genes, which primarily encode enzymes involved in virus DNA replication. Eventually, the 
L genes are expressed and new virus particles are assembled, matured, and released from 
the cell, either by cell lysis, endocytosis, or cell-cell fusion. 
 
 
IFN exerts its activities through induction of hundreds of IFN-stimulated genes (ISGs) [28]. ISGs 
especially important in antiviral defense are the PKR and the 2’-5’-OAS/RNAse L system 
(alternatively referred to as the 2’-5’A system). PKR is an important mediator of resistance against 
HSV because the absence of PKR in murine cells enhances HSV replication [29]. In addition, the 
HSV-induced expression of IFN- and the proinflammatory chemokine RANTES is dependent on 
functional PKR [15,30]. The 2’-5’A system seems to play an important role after eye infections, since Viruses 2009, 1                                       
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mice lacking RNAseL and thus the 2’-5’A system have higher mortality rates and display more severe 
disease progression [31]. In addition, studies in epithelial cells have revealed that IFN- and especially 
IFN- suppress HSV-1 replication through an RNAseL-dependent pathway [32]. It has also been 
shown that 2’-5’-OAS is a potent inhibitor of HSV replication in BHK cells [33]. As will be discussed 
later, the activity of PKR and the 2’-5’ A system is counteracted by HSV emphasizing the importance 
of PKR and the 2’-5’ A system in the innate response against HSV. Additional important ISGs 
produced during virus infections are chemokines, including IFN--inducible protein of 10 kDA (IP-10, 
CXCL10), the transcription factor IRF7, and several cellular pattern recognition receptors (PRRs), 
such as the TLRs and the RLRs [34-39].  
Type III IFNs IL-29 (IFN-1) and IL-28 (IFN-2/3) have been described to possess antiviral effects 
against HSV [27,40]. IFN-s activate the same JAK/STAT signalling pathways as type I IFNs, induce 
resistance to viral infection in several human cell lines, and upregulate expression of ISGs, such as 
MHC class I antigen, MxA, and 2’-5’OAS [41,42]. IFN-s are expressed after infection with several 
RNA viruses and treatment with dsRNA [37,41-43]. Recent data have shown that HSV induces 
expression of IFN-s in both human monocyte-derived macrophages and DCs and in murine pDCs and 
cDCs [5,27]. In addition, both IFN-and IFN- are part of a positive feedback loop that greatly 
enhances the expression of proinflammatory cytokines, chemokines, and IFNs after HSV infection 
[27]. Type III IFN inhibits HSV IE gene expression with comparable effect to IFN- implying that 
IFN-has direct antiviral effect against HSV [27,40]. Recent studies examining the role of IFN- in 
genital and generalized HSV-2 infection in mice, revealed that IFN-R knockout mice did not differ 
from wild-type mice in their ability to clear HSV infection [5]. Nevertheless, it would be interesting to 
gain insight into the role of IFN-s during HSV infection in humans, and to establish whether the type 
III IFNs will have a role in the treatment of HSV infections. 
In addition to type I and type III IFN, IFN- is a prominent mediator of antiviral immunity against 
HSV infection [24,44,45]. Studies show that IFN--mediated control of HSV in murine macrophages 
correlates with production of nitric oxide [44] and that IFN- together with IFN- and IL-12 is very 
important in control of HSV infection [24,25,46]. Furthermore, IFN- reduces reactivation of HSV 
from the neurons [45]. IFN- is mainly produced by T and NK cells [47], but also other cells, including 
macrophages, T cells, and DCs, produce IFN- after stimulation with IL-12 and IL-18 or after HSV 
infection [48-52]. Besides its direct antiviral activity, IFN- also plays a key role in initiating and 
amplifying the immune response. IFN- for instance, synergizes with HSV to induce the expression of 
proinflammatory cytokines, such as TNF-, IL-6, and IL-12 p40 [53,54]. Moreover, IFN- indirectly 
enhances cellular recognition of the virus and subsequent cytokine production through induced 
expression of potential virus PRRs, such as TLRs and RLRs [36,39,55]. 
4. HSV-Activated Signaling Pathways 
The outcome of the infection is often determined by the signal transduction pathways activated. The 
first line of defense against virus infections requires activation of multiple signal transduction 
pathways, including NF-B, MAPK pathways, and IRFs [56]. However, viruses are extremely well 
adapted to their host and part of this adaption is caused by virus manipulation of host signaling. HSV 
modulates the signaling pathways to facilitate viral gene expression and enhance viral replication, but Viruses 2009, 1                                       
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may also down-regulate specific pathways to evade immune responses and improve survival in the 
host cell. During early HSV infection, NF-B, MAPK and IRF pathways are activated [27,57]. The 
activated signaling pathways may have dual purposes; both activating cytokine expression and viral 
replication [58]. It is worth noting that the mechanism through which HSV is recognized and 
stimulates cellular gene expression is cell type dependent [16]. As will be discussed later the cell-
dependency also seems to apply for HSV evasion strategies. 
HSV does not directly activate JAK/STAT signalling pathways. JAK/STAT pathways are, 
nevertheless, very important for development of the proinflammatory response after HSV infection. 
Many HSV-induced cytokines, including IFN-, IFN-, IL-6, and IL-12, mediate phosphorylation of 
JAK proteins and subsequent phosphorylation and activation of STAT proteins [59]. The activated 
STAT proteins dimerize, translocate to the nucleus, and activate transcription through binding to the 
gamma activation site or after association with IRF9 (p48) binding to IFN-stimulated response 
elements [59]. STAT1 is a central player for IFN- and IFN--activated signal transduction and 
activity evidenced by the fact that mice and humans deficient in STAT1 are very susceptible to HSV 
infections, as discussed above [60].  
5. Evasion of the Innate Immune System by HSV 
Like most viruses, HSV has numerous countermeasures to overcome the host innate defences 
including several anti-IFN and anti-cytokine weapons and the inhibition of apoptosis. The discussion 
below will focus on the current knowledge on interaction between HSV and the host response. Figure 
3 and Table 1 summarize the strategies employed by HSV to evade the innate immune system. 
5.1. Evasion of IFN signalling and IFN effector functions 
HSV has evolved numerous mechanisms to subvert and repress the IFN- response. Besides the 
antiviral properties of IFN-, type I IFN also induces expression of antiviral proteins, such as PKR 
and the 2’-5’ A system. HSV counteracts the production of IFN, diminishes IFN-signalling, and blocks 
the actions of PKR and activation of the 2’-5’ A system through several viral products, including 
ICP0, ICP27, ICP34.5 and vhs. 
PKR plays an important role in resistance against HSV infection [29]. Moreover, HSV-induced 
expression of the chemokine RANTES and type I IFNs proceed through a PKR-dependent mechanism 
[15,30]. Therefore it is not surprising that HSV has evolved at least two mechanisms to counteract the 
activities of the kinase. The HSV L protein ICP34.5 counteracts PKR activity by recruiting the cellular 
protein phosphatase 1, which reverses the PKR-mediated phosphorylation of eIF2 [61,62]. In 
addition, the viral RNA-binding protein Us11 inhibits PKR through sequestering of dsRNA [62,63] 
and by direct binding to PKR [64]. Both the Us11 and ICP34.5 gene products are needed to 
functionally overcome the effect of IFNs [65] and ICP34.5 plays an important role for infection of 
neurons [66]. Furthermore, Us11 is important for viral inhibition of the 2’-5’-A system [67]. Knowing 
that Us11 binds to dsRNA, it will be highly interesting to define the role of Us11 in the context of 
dsRNA recognition via TLR3 or RLR. Viruses 2009, 1                                       
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In addition, it has been shown HSV inhibits 2’-5’ A/RNAse L-independent rRNA degradation by a 
mechanism involving ICP0 [68] and one study has shown that HSV uncouples this IFN-inducible 
mechanism through produced 2’-5’ A analogues [69]. 
The multifunctional viral IE proteins ICP0 and ICP27 both modulate the immune response 
generated against HSV infections in numerous ways. Most importantly, ICP0 renders HSV relatively 
resistant to IFN- and to inhibits the activation of ISGs, and this is in part mediated by inhibiting 
nuclear translocation of IRF3 [70-74]. ICP0 has been shown to be important for the virus to overcome 
STAT1-mediated antiviral activity [75]. This finding is, however, in contrast to recent publications 
showing that STAT1 and IRF3 does not play essential roles in the repression of HSV lacking ICP0 
[76,77]. The differences may however, be a matter of differences in experimental setup, including 
multiplicity of infection used and the assays performed. Recently, it was shown that ICP27 is 
necessary and sufficient for inhibition of IFN-induced STAT1 phosphorylation and partly for 
inhibition of STAT1 translocation to the nucleus [78].  
Figure 3. Innate immune evasion mechanisms of HSV. Several countermeasures against 
the host IFN and proinflammatory response have been established by HSV. For instance, 
the IRF3 pathway is inhibited by ICP0, ICP27, and ICP34.5, through distinct mechanisms. 
Also, the HSV L gene products ICP34.5 and Us11 inhibit PKR activation, with Us11 
exerting its action by direct binding to dsRNA, for which reason Us11 potentially also 
blocks activation of TLR3 and RLRs. The 2’-5’-OAS/RNAse L system is inhibited by 2’-
5’ A analogs. JAK/STAT signalling and the production of IFN- is counteracted by a 
mechanism involving ICP27.  
 Viruses 2009, 1                                       
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Table 1. Immune evasion strategies employed by HSV. 
Viral protein  Effect  Mechanism  References 
Inhibition of IFN and cytokine signalling and IFN function
ICP0  Enhanced resistance to IFN Modification of IRF3 and 
IRF7 activation 
[70-74] 
ICP27  Decreased IFN and 
cytokine expression 
Reduces IRF3 and NF-B 
activation 
[27] 
Us3  Decreased ISG expression 
(Mx) and reduced IRF3 
activation 
n.d.  [79] 
vhs  Inhibition of IFN- 
production 
Potentially because of 
reduced IRF7 activation 
[80-82] 
vhs  Inhibition of JAK/STAT 
signalling 
Induction of SOCS3, 
repression of STAT1 
activation 
[82,83] 
ICP27  Inhibition of IFN 
signalling 
Decreased STAT1 
activation and translocation 
to the nucleus 
[78] 
vhs Suppression  of 
proinflammatory 
cytokines, IFNs, and 
chemokines 
n.d.  [84] 
ICP34.5  Suppression of antiviral 
genes 
Inhibition of IRF3 
activation via interaction 
with TBK1 
[85] 
ICP34.5  Inhibition of PKR and 
PERK activity 
Reverses the PKR and 
PERK-induced 
phosphorylation of eIF2
[61,62,86] 
Us11  Inhibition of dsRNA-
dependent and PACT-
mediated activation of 
PKR 
Binds to dsRNA 
Binds to PKR 
[63] 
[64] 
Us11  Inhibition of 2’-5’ OAS  Binding to dsRNA  
(dsRNA binding domain  
of Us11 essential) 
[67] 
2’-5’A 
analog 
Inhibition of the 2’-5’ 
OAS/ RNAse L system 
2’-5’ A analogue  [69] 
ICP0  Inhibition of RNAseL-
independent rRNA 
degradation 
n.d.  [68] 
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Table 1. Cont. 
Inhibition of host gene expression    
ICP0  Inhibition of TLR-induced 
JNK and NF-B activation 
Recruitment of USP7 
binding to TRAF6 and IKK
[87] 
ICP27  Inhibition of splicing  Interacts with spliceosome 
components 
[88-90] 
ICP27  Reduction of mRNA 
stability 
n.d.  [91] 
VP16 and 
vhs 
RNA degradation  n.d.  [92] 
ICP0  Cell cycle arrest and 
disturbed cellular gene 
expression 
Upregulation of p53-
responsive genes. 
[93] 
Unknown  Inhibition of NFAT 
activation 
n.d.  [94] 
Inhibition of apoptosis     
ICP4  Inhibition of apoptosis  n.d.  [95] 
gJ  Inhibition of apoptosis  Inhibition of caspase 
activation 
[96] 
ICP27  Inhibition of apoptosis  n.d.  [97] 
ICP34.5  Inhibition of apoptosis  Inhibition of PKR activity  [62] 
  Inhibition of CTL-induced 
cell death (apoptosis) 
Downregulation of cell 
surface Fas ligand 
[98,99] 
Inhibition of autophagy and anti-microbial proteins   
ICP0 and 
ICP0 
Inhibition of SLPI  n.d.  [100] 
ICP34.5  Inhibition of autophagy  Targeting of Beclin-1  [66] 
Inhibition of complement, antigen presentation and APC function 
gC  Inhibition of complement  Binds to complement factor 
C3 
[101,102] 
gE/gI 
complex 
Blocking of Fc-mediated 
activities, including 
complement activation and 
ADCC 
Binds to Fc domain of IgG  [103] 
vhs  Inhibition of DC 
maturation and reduced 
cytokine production 
n.d.  [104,105] 
ICP47  Inhibition of antigen 
presentation by MHC I 
Interferes with TAP1/TAP2  [106-108] 
 
 Viruses 2009, 1                                       
 
 
747
Table 1. Cont. 
vhs  Inhibition of antigen 
presentation by MHC I and 
MHC II  
Interferes with MHC I 
transport. Reduces levels of 
MHC II 
[109-111] 
gB  Inhibition of MHC II-
mediated antigen 
presentation 
Inhibited expression of 
invariant chain and interacts 
with HLA-DR and HLA-
DM 
[112] 
Abbreviations: ADCC, antibody-dependent cellular cytotoxicity; CTL, cytotoxic T lymphocyte; DC, dendritic cell; HLA, 
human leukocyte antigen; ICP, infected cell protein; JAK, janus kinase; MHC, major histocompability complex; n.d., not 
determined; NFAT, nuclear factor of activated T cell; PACT, PKR-activating protein; PERK, PKR-like endoplasmic-
reticulum (ER)-resident kinase; PKR, dsRNA-activated protein kinase R; SLPI, secretory leukocyte protease inhibitor; 
SOCS, suppressor of cytokine signalling; STAT, signal transducer and activator of transcription; TAP, transporter 
accociated with antigen presentation; vhs, virion-host shutoff protein. 
 
ICP27 also inhibits the production of IFN- evidenced by the fact that virus lacking functional 
ICP27 induces higher levels of IFN- in HeLa cell and higher levels of IFN-and IFN-s in 
human macrophages [27,113]. ICP27 seems to inhibit induction IFN and cytokines in macrophages via 
inhibition of NF-B and IRF3 activation [27]. This is in accordance with results from 293T cells 
showing that ICP27 inhibits NF-B by stabilization of its inhibitor component Inhibitory kappa B 
alpha (IB [114]. Nonetheless, the inhibitory function of ICP27 might be cell specific, since reports 
have shown that ICP27 alone is sufficient to activate NF-B and MAPK pathways in Hela cells and 
CV-1 fibroblast-like cells [115-117]. 
Vhs is a multifunctional protein and an important determinant for HSV virulence [118]. The protein 
participates in many different immunmodulatory mechanisms, including regulation of IFN- 
production both in mice and murine fibroblasts after HSV infection [80,81]. In addition, HSV deficient 
in vhs is highly susceptible to IFN- [84]. This may be explained by recent findings showing that 
vhs interferes with IFN-signalling. Specifically, vhs was shown to inhibit JAK/STAT signalling and 
IRF7 expression, evidenced by findings showing that a vhs-deficient virus only weakly inhibited IFN-
signalling and expression of IRF7 [82]. The HSV- and vhs-mediated suppression of JAK/STAT 
signalling resulted in impaired expression of IRF7 and IFN- [82]. IRF7 is essential for development 
of an effective antiviral in vivo response against HSV [119]. Recent data suggest the ICP27 is major 
player in HSV-mediated inhibition of IFN signalling, since extopic expression of ICP27 efficiently 
blocked STAT1 phosphorylation and subsequent translocation to the nucleus [78]. Finally, HSV 
indirectly inhibits IFN signalling via upregulation of suppressor of cytokine signalling (SOCS) 1 and 3 
in keratinocytes and a human amnion cell line, respectively [82,120]. Of eight characterized SOCS 
proteins (SOCS1-7 and cytokine-induced SH2 protein (CIS)), only SOCS1 and 3 has been shown to 
inhibit IFN-signalling. The assays and conclusions are, however, complicated by the fact that SOCS 
expression is part of the general negative feedback loop of IFN signalling. Whether HSV-induced 
SOCS1 and 3 expression is a general mechanism of HSV resistance to IFN signalling remains to be 
determined. Viruses 2009, 1                                       
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5.2. Inhibition of cytokine and IFN gene transcription and translation 
Many cellular genes are affected by HSV infection. Initially, HSV infection may induce an antiviral 
response independent of viral replication. Next, this early proinflammatory response may be disarmed 
dependent on viral gene products [27,91,121-123]. In the following section, the immunomodulatory 
mechanisms of HSV are discussed. The mechanisms of counteracting and regulating cell gene 
expression are numerous and include HSV-mediated transcriptional repression, impaired mRNA 
stability, and inhibition of translation. 
Viral ICP27 is a well-described candidate for HSV-mediated immune evasion because it reduces 
the abundance of host mRNAs through inhibition of pre-mRNA splicing [88,124] and reduction of 
RNA stability [91]. Furthermore, ICP27 represses host cytokine gene expression [27], and together 
with vhs mediates efficient inhibition of host protein synthesis [125,126]. In addition to ICP27, also 
ICP4 has been linked to a decrease in cytokine mRNA stability [91]. HSV-mediated repression of host 
gene transcription includes an ICP27-dependent impairment of RNA polymerase (RNAP)II 
transcription, which negatively regulates some cellular genes [122]. One might speculate that a direct 
interaction between ICP27 and RNAPII [127] regulates the transcriptional function of the enzyme. 
Whether HSV-inhibition of RNAPII transcription plays a direct role in regulating cytokine gene 
expression still needs to be defined. 
IRF3 is an essential player in regulating transcription of IFN- and many proinflammatory 
cytokines and chemokines. The importance of IRF3 in anti-HSV defense is underscored by the fact 
that HSV interferes with IRF3 activation in multiple ways [27,72-74]. ICP0 has been shown to 
interfere with IRF3 and IRF7 activation of ISGs [72,74]. Interference with IRF3 includes ICP0- and 
ICP27-mediated inhibition of IRF3 nuclear accumulation, which at least for ICP0 is mediated through 
direct binding to IRF3 [27,71-73]. Finally, ICP0 has recently been shown to modulate TLR-mediated 
immune responses blocking activation of NF-B and the MAPK c-Jun NH2-terminal kinase (JNK) 
[87]. In addition to its transcriptional regulatory role, ICP0 may potentially also affect the translational 
machinery through its interaction with elongation factor-1[128]. 
Besides the role of vhs in evasion of IFN activity and degradation of mRNA, vhs also reduces the 
production of IL-1, IL-8 and CCL3 in human monocytes and macrophages after HSV infection [84]. 
Among the cytokines investigated especially IL-8 is negatively regulated, potentially explaining why 
this chemokine is rarely expressed after HSV infections. The vhs-mediated inhibition of CXCL8 
production is of great interest, taking into account that IL-8 is reported an effective adjuvant for DNA 
vaccines against HSV in mice [129]. Correspondingly, HSV lacking vhs is significantly more 
immunogenic than virus with intact vhs [130,131]. This may originate from the ability of vhs to impair 
the production of IFN, cytokines, and chemokines but may also derive from vhs-mediated inhibition of 
DC maturation, activity, and migration [105,132]. Future studies are needed to determine the 
underlying mechanisms of the vhs-impaired immune response and the decreased expression of 
immunoregulatory cytokines.  
Finally, the viral proteins ICP34.5 and Us11 inhibit PKR activity. Both PKR and PKR-like 
endoplasmic-reticulum (ER)-resident kinase (PERK) activity is inhibited by ICP34.5 [61,62,86]. PKR 
and PERK are otherwise activated after HSV infection resulting in phosphorylation of eIF2 and 
subsequent halt of protein synthesis. Furthermore, Us11 inhibits dsRNA- and PKR activator protein Viruses 2009, 1                                       
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(PACT)-mediated activation of PKR [63,64]. Collectively, Us11 and ICP34.5 block the activity of 
PKR and result in sustained levels of protein synthesis. The interference with PKR may, however, 
potentially also affect the transcriptional activation mediated by PKR.  
Recently, ICP34.5 has been added to the list of HSV-induced inhibitors of antiviral signaling via 
interaction with the signaling molecule TBK1 [85], a protein important for both IRF3 and NF-B 
signaling after RLR and TLR stimulation. Why HSV uses three proteins for inhibition of NF-B and 
IRF3 signaling (ICP0, ICP27 and ICP34.5) remains to be determined. Several explanations may be 
given, including cell dependency of evasion strategy employed by the virus and use of different viral 
proteins at different time-points of infection.  
5.3. Inhibition of autophagy and intrinsic protection 
Autophagy is the process in which the cell engulfs its own cytoplasmic components, which are then 
degraded in lysosomes. The process is a normal part of cells development and homeostasis. When 
regulated properly, autophagy participates in maintaining a balance between production and 
degradation of cellular products and subsequent recycling of the cellular constituents. Recently, the 
autophagy process has been linked to antimicrobial immunity, playing a protective role in clearance of 
intracellular parasites, bacteria and viruses [133-135]. In the context of HSV, autophagic degradation 
of HSV-1 virions has been shown to proceed via a PKR-dependent mechanism that requires the eIF2a 
kinase signalling pathway [136]. In return HSV has evolved a mechanism to evade the autophagy 
process via targeting of the essential autophagy protein Beclin-1 with ICP34.5 [66]. Of note, the 
autophagy process is primarily important for neuroprotection, but does not restrict infection in 
permissive cell cultures, indicating that the primary function of ICP34.5 in dividing cells is its 
inhibition of PKR-mediated translational arrest [137]. 
Recently, another potential antimicrobial pathway was reported to be targeted by HSV via ICP4 and 
ICP0. The studies showed that HSV downregulates secretory leukocyte proteases inhibitor (SLPI), a 
low-molecular mass anti-bacteria and anti-viral protein found in mucosal secretions. The 
downregulation was dependent on ICP0 and ICP4, since viruses deficient in ICP0 or ICP4 were unable 
to downregulate SLPI [100]. Whether the downregulation of SLPI plays an important role in HSV 
pathogenesis remains to be determined. 
6. Concluding remarks 
Although some therapeutic and diagnostic improvements for control of HSV have been developed 
during the last years, the virus is by no means under control. Therefore research on the pathogenesis of 
HSV and knowledge of overall virus-cell interactions leading to an efficient immune response are still 
most needed.  
The outcome of HSV infections is dependent on the equilibration between virus propagation and an 
effective immune response. Appropriate expression of IFNs, cytokines, and chemokines is essential for 
efficient host defense against infection. IFN and cytokines expression is mediated by interaction 
between the virus PAMPS with cellular PRRs. For HSV, TLR2, TLR3, TLR9, the MAVS pathways 
and the RNA polymerase III pathway have been identified as sensing the infection and inducing the 
production of IFN- and cytokines.  Viruses 2009, 1                                       
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HSV has evolved together with its host and developed mechanisms to overcome the effects of the 
immune response. The countermeasures are directed at several antiviral host defenses, in particular the 
cytokine and IFN system but also the complement system and antigen-dependent responses (Table 1, 
Figure 3). These countermeasures are essential for effective virus propagation and to secure an 
environment suited for virus replication and establishment of latency. Therefore investigations into the 
viral immune evasion strategies will hopefully provide additional understanding of the innate and 
adaptive immune mechanisms and reveal viral components essential for HSV. The new understanding 
of HSV infection and immunopathology might help in development of improved treatments and in 
design of vaccines. 
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